Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00423163
Status:
WITHDRAWN
Last Update Posted:
2015-09-02
First Post:
2007-01-17
Brief Title:
A Study to Evaluate the Effectiveness of Voriconazole Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Double-Blind Randomized Controlled Trial of Voriconazole VFEND Plus Micafungin MYCAMINE Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis
Status:
WITHDRAWN
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
An alternative joint industry effort will provide information on combination versus single agent therapy for treatment of aspergillosis
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the therapeutic effectiveness of voriconazole micafungin versus voriconazole alone as primary therapy for invasive aspergillosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None